SPHQ Outpaced JQUA by 500 Basis Points Over Five Years Despite Being the Riskier Trade
If you want a quality-factor tilt on U.S. large caps, the two cleanest options are the Invesco S&P 5…
247wallst.com
LRMR(LRMR)
LRMR
Next earnings: Aug 13, 2026 · Before open
Signal
Bearish Setup2↓
PRICE
Prev Close
3.89
Open
3.85
Day Range3.55 – 3.87
3.55
3.87
52W Range1.80 – 6.42
1.80
6.42
39% of range
VOLUME & SIZE
Avg Volume
4.4M
FUNDAMENTALS
P/E Ratio
-1.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.73
Low vol
Performance
1D
-5.12%5D
-3.23%1M↓
-20.12%3M
+23.49%6M
+15.09%YTD
+2.10%1Y↑
+117.32%Best: 1Y (+117.32%)Worst: 1M (-20.12%)
Quick Read
Trend—Insufficient MA data
Momentum
BEARISH
thin 0% gross marginValuation
FAIR
P/E not availableHealth
MODERATE
CR 4.3 · FCF negativeNeutral
Key MetricsTTM
Market Cap$306.37M
Revenue TTM$0.00
Net Income TTM-$166.00M
Free Cash Flow-$131.32M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity-134.1%
Return on Assets-79.6%
Debt / Equity0.02
Current Ratio4.29
EPS TTM$-2.19
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
3 strong3 concern
50/100Liquidity
4.29Strong
Leverage
0.02Strong
Coverage
0.0xConcern
ROE
-134.1%Concern
ROIC
-106.6%Concern
Cash
$85MStrong
ANALYST COVERAGE8 analysts
BUY
▲ +235.2%upside to target
Stock Health
Composite Score
3 of 5 signals bullish
5/10
Technicals
●
✗RSI RangeRSI 38 — Bearish momentum
Volume
●
✗Volume FlowDistribution — institutional selling
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 4.29 — healthy liquidity
Upcoming Events
EEarnings Report · Before OpenMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentAug 28, 2026
In 104 days
FinancialsFull statements →
Technicals
Technical SetupBEARISH
Technicals →Trend
▼ DowntrendGolden Cross · 50D leads 200D by 17.9%
-23.9% vs SMA 50 · -10.3% vs SMA 200
Momentum
RSI38.2Momentum fading
MACD-0.19Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$6.42+79.3%
EMA 50
$4.39+22.7%
EMA 200
$3.94+10.2%
Current
$3.58
52W Low
$1.80-49.7%
52-Week RangeMid-range
$1.8039th %ile$6.42
Squeeze SetupVolume-based
Distribution PressureHeavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
20-Day Money Flow
Acc days:3
Dist days:4
Edge:+1 dist
Volume Context
Avg Vol (50D)1.8M
Recent Vol (5D)
2.1M+19%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 6 analysts
Analyst revisions:EPS↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $0 | — | -$1.95 | — | ±15% | High6 |
FY2026(current) | $2.3M $463848–$5.3M | — | -$1.67 | — | ±41% | High6 |
FY2027 | $60.2M $14.0M–$120.3M | ▲ +2499.1% | -$1.27 | — | ±40% | High5 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryLRMR
Last 8Q
-13.0%avg beat
Beat 3 of 8 quartersMissed 5↓ Estimates falling-6%
Q3'24
+35%
Q4'24
-55%
Q1'25
-10%
Q2'25
+13%
Q3'25
-56%
Q4'25
-66%
Q1'26
+42%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightInsider Activity
SEC Filings →6 Buys/0 SellsNet Buying
Flynn James EDir
$5.4M
Feb 27
BUY
Flynn James EDir
$5.4M
Feb 27
BUY
Flynn James EDir
$4.2M
Feb 27
BUY
Flynn James EDir
$10.0M
Feb 27
BUY
Hamilton Thomas Edw…Dir
$500K
Feb 27
BUY
Thomas Frank EDir
$25K
Feb 27
BUY
Financials
INSTITUTIONAL OWNERSHIP
1
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
35.6M▲2
Blue Owl Capital Holdings LP
7.1M▲3
BlackRock, Inc.
3.8M▲4
MILLENNIUM MANAGEMENT LLC
3.6M▼5
AIGH Capital Management LLC
3.0M▲6
DRIEHAUS CAPITAL MANAGEMENT LLC
2.9M▲7
DAFNA Capital Management LLC
2.0M▲8
GOLDMAN SACHS GROUP INC
1.6M▲News & Activity
LRMR News
20 articles · 4h ago
We Asked Claude AI Where Ripple (XRP) Goes If ETF Inflows Hit $5 Billion
247wallst.com
iFabric Q1 Earnings Call Highlights
marketbeat.com
Interfor Q1 Earnings Call Highlights
marketbeat.com
Intermap Technologies Q1 Earnings Call Highlights
marketbeat.com
Keyera Q1 Earnings Call Highlights
marketbeat.com
K92 Mining Q1 Earnings Call Highlights
marketbeat.com
KP Tissue Q1 Earnings Call Highlights
marketbeat.com
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
marketbeat.com
Constellation Brands: Consumer Weakness Creates A Buying Opportunity
seekingalpha.com
Nextech3D.ai launches AI event marketplace targeting $1T industry - ICYMI
proactiveinvestors.com
Here's Berkshire Hathaway's new stock trades after Warren Buffett's exit
finbold.com
Playtika's Strong Guidance Signals A Real Turn (Rating Upgrade)
seekingalpha.com
Tech Heads Accompany Trump on China Trip
youtube.com
Sezzle And Pagaya Partner Up To Expand BNPL Operations
seekingalpha.com
Schneider Electric: Long Reinvestment Runway Across Electrification
seekingalpha.com
Cellebrite: Positive Q1 Results, But There Is Room For Margin Improvements
seekingalpha.com
Nebius Group, Cisco Systems, Micron Technology And More: 5 Stocks Investors Couldn't Stop Buzzing About This Week
benzinga.com
Prediction: NuScale Power Stock Is a Buy Before 2027 Due to This $1.75 Trillion Opportunity
fool.com
QQQI: The Income Feels Good, But The Bear Market Won't
seekingalpha.com
About
larimar therapeutics, inc. (nasdaq:lrmr), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. the company’s lead compound, cti-1601, is currently being evaluated in a phase 1 clinical program as a potential treatment for friedreich’s ataxia, a rare and progressive genetic disease. larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. for more information, please visit: https://larimartx.com.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Website
Francis Michael ConwayVice President & Controller
John BermanVice President of Finance & Administration
Jennifer Spokes JohanssonVice President of Legal & Compliance
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
LRMR◀ | $3.58 | -5.12% | $306M | — | — | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.27% | — | 50.3 | +398824.8% | -4085.6% | 1500 |